Journal article · 2026 · Open access
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial
Nature Medicine, 32(3), 1142–1151 · Published 7 January 2026 · DOI 10.1038/s41591-025-04185-6
In brief
“CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial” is a 2026 journal article by Fabian Müller and 33 co-authors, published in Nature Medicine. OpenAlex counts 119 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Nature Medicine.
- Citations
- 119
- Most cited in
- 2026 (119)
- Field-weighted impact
- 266.58
- References
- 40
- Authors
- 34
Abstract
Chimeric antigen receptor (CAR)-T cells are considered a powerful therapeutic tool to reset the immune system in patients with autoimmune diseases. Innovative trial designs are needed to allow feasible testing of the safety and efficacy of CAR-T cells in clinical studies. CASTLE (CAR-T cells in systemic B cell mediated autoimmune disease) is a phase 1/2a two-stage optimal design basket study that investigated the safety and efficacy of zorpocabtagene autoleucel (Zorpo-cel, also known as MB-CART19.1), an autologous CD19 CAR-T cell product, in patients with treatment-resistant systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM). The primary safety outcome was the rate of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The secondary clinical efficacy outcomes were remission of SLE according to DORIS criteria, no progression of interstitial lung disease in SSc and American College of Rheumatology (ACR) major/moderate response in IIM after 24 weeks. A total of 24 patients were enrolled (10 with SLE, 9 with SSc and 5 with IIM), all receiving a single infusion of Zorpo-cel after stopping immunosuppressive treatments and receiving standard lymphodepletion with cyclophosphamide and fludarabine. Primary and secondary endpoints of CASTLE were met. Regarding safety, no CRS higher than grade 2 and no ICANS occurred. Regarding efficacy, 22 of the 24 patients achieved predefined efficacy endpoints, with 9 out of 10 patients with SLE reaching DORIS remission, 9 out of 9 patients with SSc showing no disease progression, and 4 out of 5 patients with IIM reaching ACR major/moderate response. Furthermore, all patients remained free of glucocorticoids and any other immunosuppressive treatment over the entire observation period of 24 weeks. CASTLE suggests the feasibility, safety and efficacy of Zorpo-cel in three different autoimmune diseases and paves the way for conducting a pivotal study. ClinicalTrials.gov identifier: NCT06347718 , EudraCT identifier: 2022-001366-35 .
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Müller, F., Hagen, M., Wirsching, A., Kharboutli, S., Aigner, M., Völkl, S., Kretschmann, S., Tascilar, K., Taubmann, J., Bucci, L., Raimondo, M. G., Bergmann, C., Rothe, T., Corte, G., Tur, C., Muñoz, L., Boeltz, S., Schuster, L., Hartmann, F., . . . Schett, G. A. (2026). CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nature Medicine, 32(3), 1142–1151. https://doi.org/10.1038/s41591-025-04185-6
MLA 9
Müller, Fabian, et al. “CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.” Nature Medicine, vol. 32, no. 3, 2026, pp. 1142–1151. https://doi.org/10.1038/s41591-025-04185-6.
Chicago
Müller, Fabian, Melanie Hagen, Andreas Wirsching, Soraya Kharboutli, Michael Aigner, Simon Völkl, Sascha Kretschmann, et al. 2026. “CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.” Nature Medicine 32 (3): 1142–1151. https://doi.org/10.1038/s41591-025-04185-6.
Harvard
Müller, F. et al. (2026) ‘CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial’, Nature Medicine, 32(3), pp. 1142–1151. doi:10.1038/s41591-025-04185-6.
IEEE
F. Müller et al., “CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial,” Nature Medicine, vol. 32, no. 3, pp. 1142–1151, 2026, doi: 10.1038/s41591-025-04185-6.
BibTeX
@article{muller2026cells,
title = {{CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial}},
author = {Müller, Fabian and Hagen, Melanie and Wirsching, Andreas and Kharboutli, Soraya and Aigner, Michael and Völkl, Simon and Kretschmann, Sascha and Tascilar, Koray and Taubmann, Jule and Bucci, Laura and Raimondo, Maria Gabriella and Bergmann, Christina and Rothe, Tobias and Corte, Giulia and Tur, Carlo and Muñoz, Luis and Boeltz, Sebastian and Schuster, Louis and Hartmann, F and Garantziotis, Panagiotis and Spörl, Silvia and Vášová, Ingrid and Gerbitz, Armin and Spriewald, Bernd M. and Kiener, Hans Peter and giannarelli, diana and Locatelli, Franco and D’Agostino, Maria Antonietta and Hanssens, Linda and Miltenyi, Stefan and others},
journal = {Nature Medicine},
year = {2026},
volume = {32},
number = {3},
pages = {1142--1151},
doi = {10.1038/s41591-025-04185-6},
url = {https://doi.org/10.1038/s41591-025-04185-6}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- CD19 CAR T cells
- systemic lupus erythematosus
- systemic sclerosis
- idiopathic inflammatory myopathies
- cytokine release syndrome
- immune effector cell-associated neurotoxicity syndrome
- B cell-mediated autoimmunity
- DORIS remission
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Müller, F., Hagen, M., Wirsching, A., Kharboutli, S., Aigner, M., Völkl, S., Kretschmann, S., Tascilar, K., Taubmann, J., Bucci, L., Raimondo, M. G., Bergmann, C., Rothe, T., Corte, G., Tur, C., Muñoz, L., Boeltz, S., Schuster, L., Hartmann, F., . . . Schett, G. A. (2026). CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial. Nature Medicine, 32(3), 1142–1151. https://doi.org/10.1038/s41591-025-04185-6
How many times has this paper been cited?
119 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Fabian Müller, Melanie Hagen, Andreas Wirsching, Soraya Kharboutli, Michael Aigner, Simon Völkl, Sascha Kretschmann, Koray Tascilar, Jule Taubmann, Laura Bucci, Maria Gabriella Raimondo, Christina Bergmann and 22 more.
What is the DOI of this paper?
10.1038/s41591-025-04185-6, permanently at https://doi.org/10.1038/s41591-025-04185-6. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.